Slide 1: Aptevo Therapeutics Investor Presentation
August 2016 Aptevo Therapeutics Investor Presentation
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance, and any other statements containing the words “beli
Slide 3: Agenda
AGENDA Leadership in Bispecific Antibody Development • Aptevo today • What sets us apart • Summary
Slide 4: Aptevo: At a Glance
Aptevo: At a Glance Focus Oncology/Hematology Commercial Products 4 Product Pipeline Platform Technologies Employees Clinical: 2 Preclinical: Multiple ADAPTIR™ ~130 Headquarters Seattle, WA Q1 2016 Revenue $8M 2015 Revenue $33.6M Cash Runway $100M $65M cash (as of 8/4/16) $20M EBS future contributio
Slide 5: Executive Leadership
Executive Leadership Senior Management Board of Directors Marvin White – President & CEO Former Emergent Director; Former CFO, St. Vincent’s Health; Former Exec. Director & CFO, Lilly USA Jeff Lamothe – SVP, CFO Former Emergent VP, Finance; Former CFO, Cangene Corporation Randy Maddux – SVP, Operati
Slide 6: Our Capabilities
Our Capabilities Protein Engineering • Generate new binding domains or take partner’s mAbs and convert to ADAPTIR format • Optimize for: Screening to reduce potential for immunogenicity Binding affinity Activity Expression Manufacturability Preclinical Development • Evaluate new ADAPTIR bispecifics
Slide 7: Our Strategy
Our Strategy 1 2 3 Advance novel ADAPTIR™ product candidates, primarily in I/O Expand collaborations and partnerships Maximize cash flow from commercial portfolio to support R&D funding
Slide 8: Agenda
AGENDA Leadership in Bispecific Antibody Development • Aptevo today • What sets us apart • Summary
Slide 9: Robust and Diversified Product Portfolio
Robust and Diversified Product Portfolio Product/Candidate Technology Indication Pre-Clinical Clinical Development Stage Marketed Milestones/Highlights Phase I Phase II Phase III $1.0M WW in 2015 $14.2M WW in 2015 $10.3M WW in 2015 $2.3M WW in 2015 Executing combination clinical trials Executing Pha
Slide 10: Commercial Products to Support R&D Funding
Commercial Products to Support R&D Funding [coagulation factor IX (recombinant)] An intravenous recombinant human coagulation factor IX therapeutic for use in patients with Hemophilia B US: [Rho (D) Immune Globulin Intravenous (Human)] Canada: (Rho(D) Immune Globulin (Human) for injection) Immune Th
Slide 11: ADAPTIR – Proprietary Platform Technology
ADAPTIR™ – Proprietary Platform Technology MODULAR • New bispecifics readily assembled with potent preclinical activity • Ultimate flexibility; able to generate candidates with novel MOA • Single chain format optimized for CHO cell production; avoids issues found with other bispecifics VERSATILE Bis
Slide 12: ADAPTIR RTCC Key Advantages vs Other Bispecifics
ADAPTIR™ RTCC Key Advantages vs Other Bispecifics Highly potent Longer Half Life Reduced Toxicity Ease of Manufacturing Improved Economics Longer half-life in preclinical studies supports less frequent administration Induce target-dependent cytotoxicity at low concentrations in preclinical studies I
Slide 13: ADAPTIR – RTCC Mechanism of Action
ADAPTIR™ – RTCC Mechanism of Action ADAPTIR Bispecific Molecules Mediate RTCC: Potent Immunotherapeutic for Cancer Tumor Antigen Bispecific molecule activates T cell to kill tumor cell CD3/TCR complex Target-dependent release of cytolytic granules from T cells kills tumor T cell expansion Death of t
Slide 14: ADAPTIR Clinical Pipeline
ADAPTIR™ Clinical Pipeline Product Candidate Technology Indication Pre-Clinical Clinical Development Stage Milestones Highlights Phase I Phase II Phase III ADAPTIROtlertuzumab Monospecific ADAPTIR Bispecific RTCCMOR209/ES414* CLL mCRPC Immunooncology RTCC – Redirected T-Cell Cytotoxicity Executing c
Slide 15: ADAPTIR Clinical Stage Candidate – otlertuzumab (CLL)
ADAPTIR™ Clinical Stage Candidate – otlertuzumab (CLL) .CD37 scFv Human IgG1 Fc Description • Humanized monospecific protein therapeutic • Targeting the CD37 signaling pathway involved in B-cell malignancies • Built on ADAPTIRTM (modular protein therapeutic) platform • Demonstrated anti-tumor activi
Slide 16: ADAPTIR Clinical Stage Candidate – MOR209/ES414 (mCRPC)
ADAPTIR™ Clinical Stage Candidate – MOR209/ES414 (mCRPC) Anti-PSMA Anti-CD3 Description • Humanized bispecific protein therapeutic • Targeting PSMA and CD3, a component of the T-cell receptor • Demonstrated redirection of T-cells to kill tumor cells expressing PSMA in vitro and in vivo • Prolonged s
Slide 17: ADAPTIR Novel Preclinical Product Pipeline
ADAPTIR™ Novel Preclinical Product Pipeline Validated Platform Technology: • Bispecific ADAPTIR molecules can redirect T-cell cytotoxicity against multiple tumor targets in preclinical models Modular Bispecific Platform: • ADAPTIR platform can be used to generate bispecifics with novel MOA in Immuno
Slide 18: ADAPTIR RTCC Preclinical Candidate ROR-1/ES425
ADAPTIR™ RTCC Preclinical Candidate ROR-1/ES425 • Targets hematologic malignancies and solid tumors – Triple-negative breast cancer, ovarian cancer, NSCL, prostate kidney cancers • Preclinical in vitro and in vivo proof of concept established • Improved preclinical PK • Developing lead candidate
Slide 19: Agenda
AGENDA Leadership in Bispecific Antibody Development • Aptevo today • What sets us apart • Summary
Slide 20: Investment Fundamentals
Investment Fundamentals Spin Date: August 1, 2016 Shares Outstanding 20.2M Cash Runway $100M • $65M Today • $35M Future* Total Revenue (2015) $34M (Pro Forma) $28M Total Product Sales $6M Contracts, Grants, Collaborations Total Revenue (Q1 2016) $8M (Pro Forma) Estimated Cash Burn ~$50M -$55M (2016
Slide 21: Key Milestones – 18-24 Months
Key Milestones – 18-24 Months Development • Complete Phase 1 study of MOR209/ES414 and advance into Phase 2 development in partnership with MorphoSys • Generate new ADAPTIR-based RTCC candidates • Expand application of ADAPTIR-based candidates into new MOA • Advance new preclinical ADAPTIR-based can
Slide 22: Why Aptevo?
Why Aptevo? Established leadership and capabilities in protein-based therapies for cancer Proprietary, versatile, differentiated ADAPTIR™ technology platform Broad pipeline of clinical and preclinical development candidates Capital efficient model with commercial product portfolio to support R&D fun
Slide 23: Appendix
Appendix
Slide 24: Intellectual Property Estate
Intellectual Property Estate APTEVO owns or exclusively licenses patent rights protecting •IXINITY • ADAPTIR • otlertuzumab • MOR209/ES414 • ES210 • ES425 •5E3mAb APTEVO’S General Patent Filing • Will seek patent protection on all – Exception – existing hyperimmune products • Will practice life cycl
Slide 25: Portfolio of Marketed Products – IXINITY
Portfolio of Marketed Products IXINITY® [coagulation factor IX (recombinant)] IXINITY® is an intravenous recombinant human coagulation factor IX therapeutic for the control and prevention of bleeding episodes and for perioperative management in adults and children, =12 years of age, with Hemophilia
Slide 26: Portfolio of Marketed Products – WinRho SDF
Portfolio of Marketed Products US: [Rho (D) Immune Globulin Intravenous (Human)] Canada: (Rho (D) Immune Globulin (Human) for injection) WinRho® SDF is a Rho(D) Immune Globulin Intravenous (Human) product indicated for use in clinical situations requiring an increase in platelet count to prevent exc
Slide 27: Portfolio of Marketed Products – HepaGam B
Portfolio of Marketed Products US: [Hepatitis B Immune Globulin Intravenous (Human)] Canada: (Hepatitis B Immune Globulin (Human) Injection) HepaGam B® is the only Hepatitis B Immune Globulin approved by the FDA for the prevention of hepatitis B recurrence following liver transplantation in HBsAg-po
Slide 28: Portfolio of Marketed Products – VARIZIG
Portfolio of Marketed Products US: VARIZIG® [Varicella Zoster Immune Globulin (Human)] Canada: VariZIG® (Varicella Zoster Immune Globulin (Human)) VARIZIG® is intended for use as post-exposure prophylaxis to reduce the severity of chickenpox infections in high risk patient groups (see respective U.S